Slides on Key Decisions in HIV Care: Assessing Candidacy for Long-Acting ART

Learn the data on which patient factors may predict failure to LA CAB + RPV and who is and who is not a good candidate for this new treatment option
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Format: Microsoft PowerPoint (.ppt)
File Size: 462 KB
Released: December 1, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings